JAK2 and myelofibrosis: Passamonti et al. also suggested that PV patients homozygous for JAK2V617F are more prone to transformation into myelofibrosis with myeloid metaplasia.[9] The invention of potent JAK2-inhibitor drugs seem to open a new era in the treatment of classic MPNs.